CA-CROWN-BIOSCIENCE
8.10.2020 14:02:15 CEST | Business Wire | Press release
Crown Bioscience today announces the appointment of Pam Shang as vice president for global quality. Mrs. Shang will be instrumental in further enhancing global quality across the company, leveraging her deep expertise in implementing quality systems for pharma and biotechnology clients including in GLP, GMP and other regulated environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005432/en/
Building on CrownBio’s existing platforms, Mrs. Shang will be responsible for the strategic direction, enhancement, and growth of CrownBio’s quality systems, underlying organizational processes, and leading the associated change management.
“I am excited to welcome Pam to the leadership team,” said Armin Spura, PhD, chief executive officer of CrownBio. “With her wealth of experience in implementing global quality systems and overseeing GxP initiatives, Pam will ensure that CrownBio puts quality and our customers at the forefront of all CrownBio initiatives”.
Mrs. Shang joins CrownBio from Asahi Kasei America, a Japanese pharmaceutical company, where she was head of global quality and compliance. Pam was responsible for all regulatory matters across diverse areas including quality oversight and control, regulatory compliance, and audit management.
CrownBio has seen consistent quality improvements year-on-year, with associated enhanced client satisfaction. The new strategic initiatives led by Mrs. Shang across global operational platforms will ensure high scientific quality and a continued dedication to enhance standards and performance across the company.
“I’m delighted to bring my expertise to CrownBio”, said Pam Shang. “The quality of our work and compliance to regulatory standards is extremely important, and pivotal for CrownBio’s continued growth. My aim is to ensure that all staff are empowered with proper resources and regulatory knowledge to be successful and accountable, to foster a success-oriented, safe working environment and to ensure the scientific quality of our products and services”.
Mrs. Shang holds a BS in Management Information Systems and a minor in Business from Southern Illinois University. She also completed Master’s Program course requirements in Biotechnology at Harvard University.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005432/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom